Skip to main
CLPT

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc is demonstrating a strong growth trajectory, having reported a 17% increase in topline revenue for 2023, which is complemented by a significant reduction in cash burn. The company is poised for at least 20% revenue growth in 2024, driven by the expansion of its partnership base and the introduction of higher value service offerings. Additionally, the positive momentum is supported by key product approvals and record system installations, indicating a sustainable growth outlook for the company's offerings in minimally invasive surgical procedures.

Bears say

ClearPoint Neuro Inc demonstrated a significant reduction in cash burn throughout 2023, decreasing from $5.8 million in the first quarter to $1.2 million by the fourth quarter, indicating ongoing challenges in revenue generation. Despite the management's expectations to continue this trend of reduced cash consumption in 2024, the historical cash burn may reflect underlying operational inefficiencies and limited market demand for the company's products. Consequently, the company's financial health remains a concern, which could adversely affect investor confidence and overall stock performance.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.